USPTO serial 77977299
RHINOBLOC
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BELZER, LYDIA M
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RHINOBLOC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer L. Whitelaw
JENNIFER L. WHITELAW WHITELAW LEGAL GROUP3838 TAMIAMI TRL N FL 3NAPLES, FL 34103-3590UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Botanical extracts for use in the manufacture of nutraceuticals and pharmaceuticals; chemical extracts and active principals extracted from medicinal plants for use in the manufacture of pharmaceuticals; and botanical extracts in the manufacture of pharmaceutical preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, tincture, suppositories and ampule for injection | ACTIVE | — |
| 003 | Herbal extracts sold as an integral ingredient in cosmetics; pre-moistened non-medicated personal hygiene wipes, namely, herpes relief wipes | ACTIVE | — |
| 005 | Nutritional supplements; herbal products, namely, medicated skin and lip balms; herbal products for medical use, namely, medicated ointments, medicated oils, medicinal drinks, medicated syrups containing herbal extracts, bacterial poisons for medical purposes, and tinctures all for use in the treatment of strokes, infarcts and other cardiovascular and cerebrum diseases; herbal products for medicinal purposes, namely, herbal extracts for use as nutritional and dietary supplements; herbal products for medicinal purposes, namely, medicinal herbal extracts and medicated syrups containing herbal extracts; medicinal herb extracts; medicinal herbal extracts for medical purposes; plant extracts for medical or pharmaceutical purposes; yeast extracts for medical or pharmaceutical purposes; Medicinal botanical extracts used as component ingredients of pharmaceutical preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, tinctures, suppositories and filled ampule for injection used to treat skin ailments, for infection, degenerative, muscular, pulmonary, skeletal, endocrine, immune, neurological, cardiovascular, metabolic, inflammatory, cancer and related conditions; herbal products, namely, herbal powders being nutritional supplements; herbal products, namely, herbal powders in nutritional supplement drink mixes for nutritional purposes; herbal products, namely, herbal meal replacement powders for dietary and nutritional purposes; herbal products, namely, aromatherapy packs containing herbs used for relief from headaches, insomnia and sinus discomfort; oral preparations containing herbs or herbal extracts used to maintain health and for a wide variety of physical conditions; vitamin and mineral preparations intended for use as dietary supplements; vitamins; food supplements; pharmaceuticals and nutraceuticals, namely, vitamins and food supplements; pharmaceutical preparations, namely, appetite suppressants and lipid lowering agents; food for medically restricted diets; food supplements, namely, anti-oxidants; food for diabetics, infants and enteral feeding; botanical extracts for nutritional use, namely, for use as nutritional supplements; botanical extracts sold as an integral ingredient in nutraceuticals and pharmaceuticals for the treatment of, or relief of symptoms in, infectious diseases and adverse human health conditions, namely, infection, degenerative, muscular, pulmonary, skeletal, endocrine, immune, neurological, cardiovascular, metabolic, and/or inflammatory disorders and diseases, cancer and related conditions; anti-cough drops; cough drops; cough expectorants; cough lozenges; couch syrups; cough treatment preparations; cold sore treatment preparations; pharmaceutical antitussive-cold preparations; preparations for treating colds; analgesic preparations; analgesics; antipyretic analgesics; ibuprofen for use as an oral analgesic; multipurpose medicated antibiotic cream, analgesic balm and mentholated salve; oral analgesics; topical analgesics; pharmaceutical preparations for the treatment and prevention of herpes; vaccines for the treatment and prevention of herpes; biological preparations for the treatment and prevention of herpes; pharmaceutical preparations for the treatment of herpes simplex infection; pharmaceutical capsules for the treatment of herpes simplex infection; homeopathic preparations for the treatment of herpes and cold sores; pharmaceutical preparations for the treatment of herpes viruses; medicated topical clear fluoride gel for the treatment of herpes virus during the physical manifestation of the virus; pharmaceutical preparations for the treatment of herpes simplex virus type I or type II or herpes zoster virus, not in intravenous form; plant based antivirals; over-the-counter topical antivirals; pharmaceutical preparation with antiviral or antimicrobial properties, or both, for use in the treatment of herpetic keratitis, conjunctivitis, HIV retinopathy, viral influenza "flu", herpes simplex virus 1, herpes simplex virus 2, varicella zoster virus "herpes zoster" "shingles", cytomegalovirus, viral parainfluenza, adenovirus, viral encephalitis, viral meningitis, arbovirus, arenavirus, picornavirus, coronavirus, syntialvirus, viral infections, common colds caused by viruses, cold sores, human immune deficiency virus "HIV", roseola infantum, human herpes IV; pharmaceutical preparations for the treatment of viral diseases and disorders, namely, herpes; pharmaceutical preparations for treating immune diseases induced by virus, namely, herpes zoster and AIDS | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by HerbalScience Nutraceuticals, Inc.
- Other trademarks owned by HERBALSCIENCE, INC.
- Other trademarks owned by HERBALSCIENCE, INC.
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Similar marks named RHINOBLOC
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 6, 2010 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 5, 2010 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 1, 2009 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 8, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 19, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| Aug 3, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 3, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 31, 2009 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jul 31, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 27, 2009 | PAPER RECEIVED | — | |
| Jul 20, 2009 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 20, 2009 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 20, 2009 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 26, 2009 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 26, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 25, 2009 | PAPER RECEIVED | — | |
| Jun 23, 2009 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jun 23, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 12, 2009 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 11, 2009 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 11, 2009 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 11, 2009 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 27, 2009 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| May 26, 2009 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| May 19, 2009 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| May 18, 2009 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 18, 2009 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| May 18, 2009 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| May 18, 2009 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Apr 21, 2009 | UNTD | REQUEST TO DIVIDE UNTIMELY, REFUSED, OR WITHDRAWN | — |
| Apr 13, 2009 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 9, 2009 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Apr 9, 2009 | PAPER RECEIVED | — | |
| Apr 1, 2009 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 17, 2008 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 17, 2008 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 17, 2008 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 27, 2008 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Oct 27, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 22, 2008 | ALIE | ASSIGNED TO LIE | — |
| Oct 7, 2008 | PAPER RECEIVED | — | |
| Apr 3, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 3, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 3, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 29, 2007 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Dec 28, 2007 | NWAP | NEW APPLICATION ENTERED | — |